AQP4-IgG+ NMOSD与MOGAD中独立于发作的残疾改善与恶化相关因素:多中心队列研究
本研究基于德国NEMOS登记数据库,回顾性分析307例AQP4-IgG+ NMOSD或MOGAD成人患者的338次EDSS评估片段,评估独立于发作的确认残疾改善(CDI)与确认残疾恶化(CDW)年化率及相关因素。结果显示CDI与CDW虽罕见但确实发生,两病种间年化率无显著差异;AQP4-IgG+ NMOSD中既往发作次数较少与CDI率较高相关,强调早期预防发作的重要性。
要点
- 独立于发作的CDI和CDW在AQP4-IgG+ NMOSD与MOGAD中虽罕见但可发生。
- 两病种间调整后年化CDI与CDW率无显著差异。
- AQP4-IgG+ NMOSD中既往发作次数较少与CDI率较高相关,支持早期预防发作。
核心结论
- 独立于发作的CDI和CDW在AQP4-IgG+ NMOSD和MOGAD中虽罕见但确实发生。
- AQP4-IgG+ NMOSD中既往发作次数较少与CDI率较高相关,提示早期预防发作的重要性。
研究设计与样本
- 回顾性多中心队列研究,分析德国NEMOS登记数据库中307例AQP4-IgG+ NMOSD或MOGAD成人患者的338次EDSS评估片段。
- EDSS片段定义为无发作期间至少3次EDSS评估,且距上次发作至少90天。
- CDI和CDW定义为持续EDSS下降或上升(基线EDSS 0需≥1.5,EDSS 1.0-5.5需≥1.0,EDSS≥6.0需≥0.5),并至少维持6个月。
- 主要结局为年化CDI和CDW率,采用多变量Anderson-Gill回归模型评估危险因素。
主要发现
- 共纳入338次EDSS片段,来自307例患者(AQP4-IgG+ NMOSD 202例,MOGAD 105例;EDSS变化时中位年龄分别为56岁和41岁;女性分别占88%和49%,两组比较均p < 0.001)。
- 调整后年化CDI率在AQP4-IgG+ NMOSD为0.083(95% CI 0.029-0.233),在MOGAD为0.057(95% CI 0.012-0.277),两组间无显著差异。
- 调整后年化CDW率在AQP4-IgG+ NMOSD为0.025(95% CI 0.007-0.092),在MOGAD为0.036(95% CI 0.002-0.513),两组间无显著差异。
- 在AQP4-IgG+ NMOSD中,既往发作次数较少与CDI率较高相关(HR 0.89,95% CI 0.82-0.97)。
- 在AQP4-IgG+ NMOSD和MOGAD中,较年轻年龄均与CDI率增加相关(HR 0.96,95% CI 0.94-0.99)。
关键数值与推荐
- CDI和CDW的EDSS变化阈值:基线EDSS 0需≥1.5,EDSS 1.0-5.5需≥1.0,EDSS≥6.0需≥0.5。
- CDI和CDW需在至少6个月后确认持续。
- EDSS片段需包含至少3次无发作期间的评估,且距上次发作至少90天。
临床怎么用
- 临床中应关注AQP4-IgG+ NMOSD和MOGAD患者独立于发作的残疾变化,定期进行EDSS评估。
- 对于AQP4-IgG+ NMOSD患者,减少既往发作次数可能有助于提高残疾改善机会,应强调早期预防发作。
- 年轻患者可能更易出现残疾改善,但需结合个体情况综合评估。
局限性
- 回顾性研究设计。
- CDI和CDW事件数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Disability trajectories in aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are primarily driven by attack-related damage. Confirmed disability worsening (CDW) independent of attacks has been described but occurs infrequently in AQP4-IgG+ NMOSD and MOGAD. Confirmed disability improvement (CDI) has not been evaluated in large cohorts. We determined the frequency of CDI and CDW independent of attacks and identified clinical factors associated with these outcomes in AQP4-IgG+ NMOSD and MOGAD. METHODS: This retrospective, multicenter cohort study analyzed data from the German Neuromyelitis Optica Study Group (NEMOS) registry. Adult patients with AQP4-IgG+ NMOSD or MOGAD and longitudinal Expanded Disability Status Scale (EDSS) assessments were included. EDSS episodes were defined as periods with ≥3 EDSS assessments without attacks, obtained ≥90 days after attack. CDW and CDI were defined as sustained EDSS increase or decrease (≥1.5 for baseline EDSS 0; ≥1.0 for EDSS 1.0-5.5; ≥0.5 for EDSS ≥6.0) confirmed after at least 6 months. The primary outcomes were annualized CDI and CDW rates. Risk factors were assessed using multivariable Anderson-Gill regression models. RESULTS: A total of 338 EDSS episodes of 307 patients (n: 202/105, median age at EDSS change: 56/41 years, 88/49% female, both p < 0.001; AQP4-IgG+ NMOSD/MOGAD) were included. Adjusted annualized CDI and CDW rates did not differ between AQP4-IgG+ NMOSD (CDI: 0.083, 95% CI 0.029-0.233; CDW: 0.025, 95% CI 0.007-0.092) and MOGAD (CDI: 0.057, 95% CI 0.012-0.277; CDW: 0.036, 95% CI 0.002-0.513). In AQP4-IgG+ NMOSD, a lower number of prior attacks was associated with higher CDI rates (hazard ratio [HR] 0.89, 95% CI 0.82-0.97). Younger age was associated with increased CDI rates in both AQP4-IgG+ NMOSD and MOGAD (HR 0.96, 95% CI 0.94-0.99, for both). DISCUSSION: CDI and CDW independent of attacks, although rare, occur in AQP4-IgG+ NMOSD and MOGAD. The association between fewer prior attacks and higher CDI rates in AQP4-IgG+ NMOSD underscores the importance of early attack prevention. Limitations include the retrospective design, and the limited number of CDI and CDW events.
引用
- Engels D, Schindler P, Havla J, et al. Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study. Neurology. 2026. PMID: 42391599. doi:10.1212/WNL.0000000000218199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。